{"url_path":"/sec/engnw/8-k/2026-06-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Information.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-270384-index.html","accession_number":"0001193125-26-270384","cik":"0001980845","ticker":"ENGN","issuer_name":"enGene Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1980845/0001193125-26-270384-index.html","primary_entity_key":"0001980845","primary_entity_name":"enGene Therapeutics Inc."},"word_count":673,"has_tables":true,"body_markdown":"Item 8.01 Other Information.\n\nAppointment of Interim Chief Medical Officer\n\nOn June 14, 2026, the Board appointed Dr. William Grossman, a current member of the Board and chair of the Board’s Research and Development Committee, to the position of Interim Chief Medical Officer of the Company, effective June 15, 2026. The Company, through its subsidiary enGene USA, expects to enter into a part-time employment agreement with Dr. Grossman that will provide for his employment by the Company for up to 15 hours per week. If the parties enter into the Grossman Employment Agreement, the Company intends to file a copy of such agreement as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ended July 31, 2026. Dr. Grossman will continue to serve as a member of the Board following his appointment as Interim Chief Medical Officer. In connection with Dr. Grossman’s appointment, the Board has determined to dissolve the Research & Development Committee of the Board.\n\nAs a result of his appointment, Dr. Grossman will no longer be deemed an “independent director” under the applicable rules and regulations of the U.S. Securities and Exchange Commission and the Nasdaq Stock Market listing rules, and will temporarily cease receiving compensation as a director during his tenure as the Interim Chief Medical Officer of the Company.\n\nFor more information regarding Dr. Grossman, including his biography, please refer to the Company’s Annual Report on Form 10-K filed with the SEC on December 22, 2025, as amended by Amendment No. 1 of the Company’s Annual Report on Form 10-K/A filed with the SEC on February 19, 2026.\n\nStrategic Restructuring\n\n \n\nThe information set forth in Item 2.05 of this Current Report on Form 8-K is incorporated herein by reference as if set forth herein.\n\nSeparation of Certain Executive Officers\n\nIn connection with the strategic restructuring, on June 15, 2026, the Company announced that Lee Giguere, Chief Legal Officer and Secretary and Alex Nichols, Chief Strategy and Operations Officer will each depart the Company effective July 15, 2026. In addition, Anthony Cheung, Chief Scientific Officer will conclude his employment with the Company effective September 30, 2026, but is expected to continue with the Company as a consultant.\n\nThe Company, through its subsidiary enGene USA, expects to enter into a separation and general release agreement with each of Mr. Giguere (the “Giguere Separation Agreement”) and Dr. Nichols (the “Nichols Separation Agreement”). In addition, the Company, through its subsidiary enGene, Inc., expects to enter into a transition services agreement and general release with Dr. Cheung, which is expected to include a one-year consulting arrangement commencing October 1, 2026 (the “Cheung Transition Agreement”).\n\nIf the respective parties enter into the Giguere Separation Agreement, the Nichols Separation Agreement or the Cheung Transition Agreement, as the case may be, the Company intends to file a copy of each such agreement as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ended July 31, 2026.\n\nCash Retention Agreements\n\nAs discussed above in Item 2.05, in connection with the strategic restructuring, the Company, through its subsidiary enGene USA, expects to enter into performance-based cash retention bonus agreements with each of (i) Matthew Boyd, Chief Regulatory Officer, (ii) Jill Buck, Chief Development Officer, (iii) Joan Connolly, Chief Technology Officer and (iv) Amy Pott, Chief Global Commercialization Officer (collectively, the “Executive Cash Retention Agreements”). Additionally, the Company, through its subsidiaries enGene USA and enGene Inc. expects to enter into performance-based cash retention bonus agreements with certain non-executive employees (collectively, the “Employee Cash Retention Agreements”, and together with the Executive Cash Retention Agreements, the “Cash Retention Agreements”).\n\nAdditional information regarding the applicable performance conditions and aggregate amount of estimated Cash Retention Agreements is set forth in Item 2.05 hereto.\n\n \n\n \n\n## The foregoing descriptions of the Executive Cash Retention Agreements and the Employee Cash Retention Agreements are qualified in their entirety by the complete text of the respective agreements, forms of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ended July 31, 2026."}